about us

ImmunoCellular Therapeutics, Ltd.  is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company’s lead product candidate, ICT-107, is a patient-specific, dendritic cell-based immunotherapy targeting glioblastoma and is currently being studied in an international Phase 3 trial. ImmunoCellular’s pipeline also includes: ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting CD133 found in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting ovarian cancer; and the Stem-to-T-cell research program which engineers hematopoietic stem cells to generate cytotoxic T cells.

About Us Collage

ICT-107 is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. A phase 3 registrational trial in patients with newly diagnosed glioblastoma, the most common and lethal form of brain cancer, has been initiated. The phase 3 registrational trial is designed as a randomized, double-blind, placebo-controlled study of at least 500 HLA-A2+ subjects, which will be conducted at about 120 sites in the US, Canada and the EU. The primary endpoint in the trial is overall survival, which the FDA and EU regulators have stated is the appropriate endpoint for registrational clinical studies in glioblastoma. Secondary endpoints include progression-free survival and safety, as well as overall survival in the two pre-specified MGMT subgroups.

ICT-121 is a DC immunotherapeutic that targets CD133, an antigen commonly associated with cancer stem cells (CSCs). We are conducting a 20-patient Phase 1 clinical trial in patients with recurrent glioblastoma.

ICT-140 is a DC immunotherapeutic that targets seven different antigens associated with ovarian cancer, including those expressed by CSCs. A phase 2 trial is awaiting a partnership or other financing to proceed.

ImmunoCellular’s goal is to become an industry-leading, independent, commercial-stage cancer immunotherapy company. We have a development pipeline of therapeutically important, commercially attractive product candidates, and a highly productive, proprietary cancer immunotherapy platform. These assets have the potential to transform the treatment of cancer, benefit patients and create value for our stakeholders.

Copyright 2017 by Immunocellular Therapeutics, Ltd.
All Rights Reserved